Q-omics provides the consensus-scored TSPAN16 profile across patient tissues and cancer cell-line models. TSPAN16 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TSPAN16 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TSPAN16 RNA expression shows 12,993 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where TSPAN16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN16 survival associations across molecular data types. TSPAN16 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN16 RNA expression–survival associations across cancer types. High TSPAN16 expression shows unfavorable associations in UVM, THCA, MESO, LGG and ACC, but favorable associations in HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TSPAN16 RNA expression.
This table summarizes TSPAN16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN16 shows lower tumor expression in ESCA and higher tumor expression in KIRC, HNSC, READ, UCEC and BRCA. The KIRC box plot shows higher TSPAN16 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p < 0.001).
This table shows molecular features associated with TSPAN16 in patient tissues and cancer cell lines. In patient samples, TSPAN16 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
